OncotoX-AML | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

9,262 results for “OncotoX-AML”

Omeros Reports Breakthrough Primate Study Results for Novel AML Therapeutic OncotoX-AML

Omeros Forms Elite Clinical Steering Committee to Advance Novel AML Therapeutic Program

Omeros Secures $240M Novo Nordisk Deal as Narsoplimab Approaches FDA Approval for TATMA

Obe-cel Approved for R/R B-Cell ALL, CAR T-Cell Therapy Shows Promise in AML

Hemogenyx Pharmaceuticals Advances HG-CT-1 into Phase I Clinical Trials for Relapsed/Refractory AML

Curis' Emavusertib Shows Promise in FLT3-Mutated AML Patients

ImCheck's ICT01 Shows Promise in Treating AML in Older, Unfit Patients

Ziftomenib Shows Promise in Treatment of Relapsed/Refractory AML

FDA Grants Orphan Drug Designations to Two Novel AML Therapies

Latest Advances in AML Treatment Highlighted at ASH 2024 Annual Meeting

Page 1 of 113